PMID: 6991733Jul 18, 1980Paper

Adjuvant chemotherapy for stage II and III breast carcinoma

JAMA : the Journal of the American Medical Association
J A CapriniE F Scanlon

Abstract

Stage II or III breast carcinoma patients were assigned to one of three adjuvant chemotherapy groups after mastectomy. The efficacy of melphalan, vs cyclophosphamide, fluorouracil, and prednisone (CFP), vs CFP plus BCG vaccine was compared in 173 patients treated for five days every six weeks for the first postoperative year. Tumor size, unfavorable local signs, extent of axillary nodal involvement, menopausal status, and participating hospital were considered in assigning patients to treatment groups. The median follow-up time was 26 months; 24.2% of the patients were studied for more than three years. Recurrent disease occurred in 31.6% of the patients in the melphalan group and in 13.4% and 13.2% in the other two groups. Six patients died of metastatic tumor; three others died of other causes. A favorable significant difference exists for polychemotherapy in prolonging disease-free interval in our series.

Citations

Jan 1, 1997·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·J M Debois
Feb 15, 1984·Klinische Wochenschrift·G A Nagel
Dec 1, 1983·European Journal of Cancer & Clinical Oncology·H T Mouridsen, T Palshof
Dec 11, 1985·The Journal of Rural Health : Official Journal of the American Rural Health Association and the National Rural Health Care Association·J K CooperL E Heller
Jul 1, 1982·Cancer·J T CarpenterS J Soong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.